APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GABA Receptor Agonist Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GABA Receptor Agonist Drug Market Outlook and Growth Opportunities 2026

Report ID 173993680422 December 2025206 pages

Choose your research edition.

Industry ResearchGABA Receptor Agonist Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal GABA Receptor Agonist Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal GABA Receptor Agonist Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GABA Receptor Agonist Drug Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal GABA Receptor Agonist Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global GABA Receptor Agonist Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GABA Receptor Agonist Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GABA Receptor Agonist Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GABA Receptor Agonist Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GABA Receptor Agonist Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GABA Receptor Agonist Drug market include Novartis, Eli Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca, XenoPort, VIVUS, sanofi-aventis and OVATION Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GABA Receptor Agonist Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GABA Receptor Agonist Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GABA Receptor Agonist Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GABA Receptor Agonist Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

GABA Receptor Agonist Drug Segment by Company

Novartis

Eli Lilly and Company

Pfizer

GlaxoSmithKline

AstraZeneca

XenoPort

VIVUS

sanofi-aventis

OVATION Pharmaceuticals

Osmotica Pharmaceutical

NovaDel Pharma

H.LundBeck, Merck and Co

Elan Corporation

Biocodex

Athena Drug Delivery Solutions

Advicenne

GABA Receptor Agonist Drug Segment by Type

Baclofen

Bamaluzole

Phenibut

Gaboxadol

Klonopin (clonazepam)

Tiagbine

GABA Receptor Agonist Drug Segment by Application

Alzheimer

Epilepsy and Seizure

Obesity and Alcoholism

Anxiety and Sleep Disorders

Psychiatric Disorders and Depression

Attention Deficit Hyperactivity Disorder (ADHD)

GABA Receptor Agonist Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GABA Receptor Agonist Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GABA Receptor Agonist Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GABA Receptor Agonist Drug significant trends, drivers, influence factors in global and regions.

6. To analyze GABA Receptor Agonist Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABA Receptor Agonist Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GABA Receptor Agonist Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABA Receptor Agonist Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GABA Receptor Agonist Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GABA Receptor Agonist Drug industry.

Chapter 3: Detailed analysis of GABA Receptor Agonist Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GABA Receptor Agonist Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GABA Receptor Agonist Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GABA Receptor Agonist Drug Industry Trends Table 2. GABA Receptor Agonist Drug Industry Drivers Table 3. GABA Receptor Agonist Drug Industry Opportunities and Challenges Table 4. GABA Receptor Agonist Drug Industry Restraints Table 5. Global GABA Receptor Agonist Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GABA Receptor Agonist Drug Revenue Share by Company (2021-2026) Table 7. Global GABA Receptor Agonist Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global GABA Receptor Agonist Drug Sales Volume Share by Company (2021-2026) Table 9. Global GABA Receptor Agonist Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global GABA Receptor Agonist Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global GABA Receptor Agonist Drug Key Company Manufacturing Base & Headquarters Table 12. Global GABA Receptor Agonist Drug Company, Product Type & Application Table 13. Global GABA Receptor Agonist Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GABA Receptor Agonist Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Baclofen Table 18. Significant Companies of Bamaluzole Table 19. Significant Companies of Phenibut Table 20. Significant Companies of Gaboxadol Table 21. Significant Companies of Klonopin (clonazepam) Table 22. Significant Companies of Tiagbine Table 23. Global GABA Receptor Agonist Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global GABA Receptor Agonist Drug Sales Volume by Type (2021-2026) & (k units) Table 25. Global GABA Receptor Agonist Drug Sales Volume by Type (2027-2032) & (k units) Table 26. Global GABA Receptor Agonist Drug Sales Volume Share by Type (2021-2026) Table 27. Global GABA Receptor Agonist Drug Sales Volume Share by Type (2027-2032) Table 28. Global GABA Receptor Agonist Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global GABA Receptor Agonist Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global GABA Receptor Agonist Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global GABA Receptor Agonist Drug Sales Value Share by Type (2021-2026) Table 32. Global GABA Receptor Agonist Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Alzheimer Table 34. Significant Companies of Epilepsy and Seizure Table 35. Significant Companies of Obesity and Alcoholism Table 36. Significant Companies of Anxiety and Sleep Disorders Table 37. Significant Companies of Psychiatric Disorders and Depression Table 38. Significant Companies of Attention Deficit Hyperactivity Disorder (ADHD) Table 39. Global GABA Receptor Agonist Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global GABA Receptor Agonist Drug Sales Volume by Application (2021-2026) & (k units) Table 41. Global GABA Receptor Agonist Drug Sales Volume by Application (2027-2032) & (k units) Table 42. Global GABA Receptor Agonist Drug Sales Volume Share by Application (2021-2026) Table 43. Global GABA Receptor Agonist Drug Sales Volume Share by Application (2027-2032) Table 44. Global GABA Receptor Agonist Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global GABA Receptor Agonist Drug Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global GABA Receptor Agonist Drug Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global GABA Receptor Agonist Drug Sales Value Share by Application (2021-2026) Table 48. Global GABA Receptor Agonist Drug Sales Value Share by Application (2027-2032) Table 49. Global GABA Receptor Agonist Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 50. Global GABA Receptor Agonist Drug Sales by Region (2021-2026) & (k units) Table 51. Global GABA Receptor Agonist Drug Sales Market Share by Region (2021-2026) Table 52. Global GABA Receptor Agonist Drug Sales by Region (2027-2032) & (k units) Table 53. Global GABA Receptor Agonist Drug Sales Market Share by Region (2027-2032) Table 54. Global GABA Receptor Agonist Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global GABA Receptor Agonist Drug Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global GABA Receptor Agonist Drug Sales Value Share by Region (2021-2026) Table 57. Global GABA Receptor Agonist Drug Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global GABA Receptor Agonist Drug Sales Value Share by Region (2027-2032) Table 59. Global GABA Receptor Agonist Drug Market Average Price (US$/unit) by Region (2021-2026) Table 60. Global GABA Receptor Agonist Drug Market Average Price (US$/unit) by Region (2027-2032) Table 61. Global GABA Receptor Agonist Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 62. Global GABA Receptor Agonist Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global GABA Receptor Agonist Drug Sales by Country (2021-2026) & (k units) Table 64. Global GABA Receptor Agonist Drug Sales Market Share by Country (2021-2026) Table 65. Global GABA Receptor Agonist Drug Sales by Country (2027-2032) & (k units) Table 66. Global GABA Receptor Agonist Drug Sales Market Share by Country (2027-2032) Table 67. Global GABA Receptor Agonist Drug Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global GABA Receptor Agonist Drug Sales Value Market Share by Country (2021-2026) Table 69. Global GABA Receptor Agonist Drug Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global GABA Receptor Agonist Drug Sales Value Market Share by Country (2027-2032) Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Novartis GABA Receptor Agonist Drug Product Portfolio Table 75. Novartis Recent Development Table 76. Eli Lilly and Company Company Information Table 77. Eli Lilly and Company Business Overview Table 78. Eli Lilly and Company GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Eli Lilly and Company GABA Receptor Agonist Drug Product Portfolio Table 80. Eli Lilly and Company Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Pfizer GABA Receptor Agonist Drug Product Portfolio Table 85. Pfizer Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline GABA Receptor Agonist Drug Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. AstraZeneca GABA Receptor Agonist Drug Product Portfolio Table 95. AstraZeneca Recent Development Table 96. XenoPort Company Information Table 97. XenoPort Business Overview Table 98. XenoPort GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. XenoPort GABA Receptor Agonist Drug Product Portfolio Table 100. XenoPort Recent Development Table 101. VIVUS Company Information Table 102. VIVUS Business Overview Table 103. VIVUS GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. VIVUS GABA Receptor Agonist Drug Product Portfolio Table 105. VIVUS Recent Development Table 106. sanofi-aventis Company Information Table 107. sanofi-aventis Business Overview Table 108. sanofi-aventis GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. sanofi-aventis GABA Receptor Agonist Drug Product Portfolio Table 110. sanofi-aventis Recent Development Table 111. OVATION Pharmaceuticals Company Information Table 112. OVATION Pharmaceuticals Business Overview Table 113. OVATION Pharmaceuticals GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. OVATION Pharmaceuticals GABA Receptor Agonist Drug Product Portfolio Table 115. OVATION Pharmaceuticals Recent Development Table 116. Osmotica Pharmaceutical Company Information Table 117. Osmotica Pharmaceutical Business Overview Table 118. Osmotica Pharmaceutical GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Osmotica Pharmaceutical GABA Receptor Agonist Drug Product Portfolio Table 120. Osmotica Pharmaceutical Recent Development Table 121. NovaDel Pharma Company Information Table 122. NovaDel Pharma Business Overview Table 123. NovaDel Pharma GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. NovaDel Pharma GABA Receptor Agonist Drug Product Portfolio Table 125. NovaDel Pharma Recent Development Table 126. H.LundBeck, Merck and Co Company Information Table 127. H.LundBeck, Merck and Co Business Overview Table 128. H.LundBeck, Merck and Co GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. H.LundBeck, Merck and Co GABA Receptor Agonist Drug Product Portfolio Table 130. H.LundBeck, Merck and Co Recent Development Table 131. Elan Corporation Company Information Table 132. Elan Corporation Business Overview Table 133. Elan Corporation GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Elan Corporation GABA Receptor Agonist Drug Product Portfolio Table 135. Elan Corporation Recent Development Table 136. Biocodex Company Information Table 137. Biocodex Business Overview Table 138. Biocodex GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Biocodex GABA Receptor Agonist Drug Product Portfolio Table 140. Biocodex Recent Development Table 141. Athena Drug Delivery Solutions Company Information Table 142. Athena Drug Delivery Solutions Business Overview Table 143. Athena Drug Delivery Solutions GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Athena Drug Delivery Solutions GABA Receptor Agonist Drug Product Portfolio Table 145. Athena Drug Delivery Solutions Recent Development Table 146. Advicenne Company Information Table 147. Advicenne Business Overview Table 148. Advicenne GABA Receptor Agonist Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Advicenne GABA Receptor Agonist Drug Product Portfolio Table 150. Advicenne Recent Development Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. GABA Receptor Agonist Drug Distributors List Table 154. GABA Receptor Agonist Drug Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. GABA Receptor Agonist Drug Product Image Figure 2. Global GABA Receptor Agonist Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GABA Receptor Agonist Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global GABA Receptor Agonist Drug Sales (2021-2032) & (k units) Figure 5. Global GABA Receptor Agonist Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global GABA Receptor Agonist Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Baclofen Image Figure 10. Bamaluzole Image Figure 11. Phenibut Image Figure 12. Gaboxadol Image Figure 13. Klonopin (clonazepam) Image Figure 14. Tiagbine Image Figure 15. Global GABA Receptor Agonist Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global GABA Receptor Agonist Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global GABA Receptor Agonist Drug Sales Volume Share by Type (2021-2032) Figure 18. Global GABA Receptor Agonist Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global GABA Receptor Agonist Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global GABA Receptor Agonist Drug Sales Value Share by Type (2021-2032) Figure 21. Alzheimer Image Figure 22. Epilepsy and Seizure Image Figure 23. Obesity and Alcoholism Image Figure 24. Anxiety and Sleep Disorders Image Figure 25. Psychiatric Disorders and Depression Image Figure 26. Attention Deficit Hyperactivity Disorder (ADHD) Image Figure 27. Global GABA Receptor Agonist Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global GABA Receptor Agonist Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global GABA Receptor Agonist Drug Sales Volume Share by Application (2021-2032) Figure 30. Global GABA Receptor Agonist Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global GABA Receptor Agonist Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global GABA Receptor Agonist Drug Sales Value Share by Application (2021-2032) Figure 33. Global GABA Receptor Agonist Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 34. Global GABA Receptor Agonist Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global GABA Receptor Agonist Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global GABA Receptor Agonist Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America GABA Receptor Agonist Drug Sales Value (2021-2032) & (US$ Million) Figure 38. North America GABA Receptor Agonist Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe GABA Receptor Agonist Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Europe GABA Receptor Agonist Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific GABA Receptor Agonist Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific GABA Receptor Agonist Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America GABA Receptor Agonist Drug Sales Value (2021-2032) & (US$ Million) Figure 44. South America GABA Receptor Agonist Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa GABA Receptor Agonist Drug Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa GABA Receptor Agonist Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. GABA Receptor Agonist Drug Value Chain Figure 132. Manufacturing Cost Structure Figure 133. GABA Receptor Agonist Drug Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Baclofen
  • Bamaluzole
  • Phenibut
  • Gaboxadol
  • Klonopin (clonazepam)
  • Tiagbine
Applications
  • Alzheimer
  • Epilepsy and Seizure
  • Obesity and Alcoholism
  • Anxiety and Sleep Disorders
  • Psychiatric Disorders and Depression
  • Attention Deficit Hyperactivity Disorder (ADHD)
Companies covered
  • Novartis
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • XenoPort
  • VIVUS
  • sanofi-aventis
  • OVATION Pharmaceuticals
  • Osmotica Pharmaceutical
  • NovaDel Pharma
  • H.LundBeck, Merck and Co
  • Elan Corporation
  • Biocodex
  • Athena Drug Delivery Solutions
  • Advicenne

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GABA Receptor Agonist Drug Sales Value (2021-2032)
  4. 1.2.2 Global GABA Receptor Agonist Drug Sales Volume (2021-2032)
  5. 1.2.3 Global GABA Receptor Agonist Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GABA Receptor Agonist Drug Market Dynamics
  1. 2.1 GABA Receptor Agonist Drug Industry Trends
  2. 2.2 GABA Receptor Agonist Drug Industry Drivers
  3. 2.3 GABA Receptor Agonist Drug Industry Opportunities and Challenges
  4. 2.4 GABA Receptor Agonist Drug Industry Restraints
3 GABA Receptor Agonist Drug Market by Company
  1. 3.1 Global GABA Receptor Agonist Drug Company Revenue Ranking in 2025
  2. 3.2 Global GABA Receptor Agonist Drug Revenue by Company (2021-2026)
  3. 3.3 Global GABA Receptor Agonist Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global GABA Receptor Agonist Drug Average Price by Company (2021-2026)
  5. 3.5 Global GABA Receptor Agonist Drug Company Ranking (2024-2026)
  6. 3.6 Global GABA Receptor Agonist Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global GABA Receptor Agonist Drug Company Product Type and Application
  8. 3.8 Global GABA Receptor Agonist Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GABA Receptor Agonist Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GABA Receptor Agonist Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GABA Receptor Agonist Drug Market by Type
  1. 4.1 GABA Receptor Agonist Drug Type Introduction
  2. 4.1.1 Baclofen
  3. 4.1.2 Bamaluzole
  4. 4.1.3 Phenibut
  5. 4.1.4 Gaboxadol
  6. 4.1.5 Klonopin (clonazepam)
  7. 4.1.6 Tiagbine
  8. 4.2 Global GABA Receptor Agonist Drug Sales Volume by Type
  9. 4.2.1 Global GABA Receptor Agonist Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global GABA Receptor Agonist Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global GABA Receptor Agonist Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global GABA Receptor Agonist Drug Sales Value by Type
  13. 4.3.1 Global GABA Receptor Agonist Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global GABA Receptor Agonist Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global GABA Receptor Agonist Drug Sales Value Share by Type (2021-2032)
5 GABA Receptor Agonist Drug Market by Application
  1. 5.1 GABA Receptor Agonist Drug Application Introduction
  2. 5.1.1 Alzheimer
  3. 5.1.2 Epilepsy and Seizure
  4. 5.1.3 Obesity and Alcoholism
  5. 5.1.4 Anxiety and Sleep Disorders
  6. 5.1.5 Psychiatric Disorders and Depression
  7. 5.1.6 Attention Deficit Hyperactivity Disorder (ADHD)
  8. 5.2 Global GABA Receptor Agonist Drug Sales Volume by Application
  9. 5.2.1 Global GABA Receptor Agonist Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global GABA Receptor Agonist Drug Sales Volume by Application (2021-2032)
  11. 5.2.3 Global GABA Receptor Agonist Drug Sales Volume Share by Application (2021-2032)
  12. 5.3 Global GABA Receptor Agonist Drug Sales Value by Application
  13. 5.3.1 Global GABA Receptor Agonist Drug Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global GABA Receptor Agonist Drug Sales Value by Application (2021-2032)
  15. 5.3.3 Global GABA Receptor Agonist Drug Sales Value Share by Application (2021-2032)
6 GABA Receptor Agonist Drug Regional Sales and Value Analysis
  1. 6.1 Global GABA Receptor Agonist Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GABA Receptor Agonist Drug Sales by Region (2021-2032)
  3. 6.2.1 Global GABA Receptor Agonist Drug Sales by Region: 2021-2026
  4. 6.2.2 Global GABA Receptor Agonist Drug Sales by Region (2027-2032)
  5. 6.3 Global GABA Receptor Agonist Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GABA Receptor Agonist Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global GABA Receptor Agonist Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global GABA Receptor Agonist Drug Sales Value by Region (2027-2032)
  9. 6.5 Global GABA Receptor Agonist Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GABA Receptor Agonist Drug Sales Value (2021-2032)
  12. 6.6.2 North America GABA Receptor Agonist Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GABA Receptor Agonist Drug Sales Value (2021-2032)
  15. 6.7.2 Europe GABA Receptor Agonist Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GABA Receptor Agonist Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GABA Receptor Agonist Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GABA Receptor Agonist Drug Sales Value (2021-2032)
  21. 6.9.2 South America GABA Receptor Agonist Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GABA Receptor Agonist Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GABA Receptor Agonist Drug Sales Value Share by Country, 2025 VS 2032
7 GABA Receptor Agonist Drug Country-level Sales and Value Analysis
  1. 7.1 Global GABA Receptor Agonist Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GABA Receptor Agonist Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GABA Receptor Agonist Drug Sales by Country (2021-2032)
  4. 7.3.1 Global GABA Receptor Agonist Drug Sales by Country (2021-2026)
  5. 7.3.2 Global GABA Receptor Agonist Drug Sales by Country (2027-2032)
  6. 7.4 Global GABA Receptor Agonist Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global GABA Receptor Agonist Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global GABA Receptor Agonist Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GABA Receptor Agonist Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GABA Receptor Agonist Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GABA Receptor Agonist Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis GABA Receptor Agonist Drug Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company GABA Receptor Agonist Drug Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer GABA Receptor Agonist Drug Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline GABA Receptor Agonist Drug Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca GABA Receptor Agonist Drug Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 XenoPort
  32. 8.6.1 XenoPort Company Information
  33. 8.6.2 XenoPort Business Overview
  34. 8.6.3 XenoPort GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 XenoPort GABA Receptor Agonist Drug Product Portfolio
  36. 8.6.5 XenoPort Recent Developments
  37. 8.7 VIVUS
  38. 8.7.1 VIVUS Company Information
  39. 8.7.2 VIVUS Business Overview
  40. 8.7.3 VIVUS GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 VIVUS GABA Receptor Agonist Drug Product Portfolio
  42. 8.7.5 VIVUS Recent Developments
  43. 8.8 sanofi-aventis
  44. 8.8.1 sanofi-aventis Company Information
  45. 8.8.2 sanofi-aventis Business Overview
  46. 8.8.3 sanofi-aventis GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 sanofi-aventis GABA Receptor Agonist Drug Product Portfolio
  48. 8.8.5 sanofi-aventis Recent Developments
  49. 8.9 OVATION Pharmaceuticals
  50. 8.9.1 OVATION Pharmaceuticals Company Information
  51. 8.9.2 OVATION Pharmaceuticals Business Overview
  52. 8.9.3 OVATION Pharmaceuticals GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 OVATION Pharmaceuticals GABA Receptor Agonist Drug Product Portfolio
  54. 8.9.5 OVATION Pharmaceuticals Recent Developments
  55. 8.10 Osmotica Pharmaceutical
  56. 8.10.1 Osmotica Pharmaceutical Company Information
  57. 8.10.2 Osmotica Pharmaceutical Business Overview
  58. 8.10.3 Osmotica Pharmaceutical GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Osmotica Pharmaceutical GABA Receptor Agonist Drug Product Portfolio
  60. 8.10.5 Osmotica Pharmaceutical Recent Developments
  61. 8.11 NovaDel Pharma
  62. 8.11.1 NovaDel Pharma Company Information
  63. 8.11.2 NovaDel Pharma Business Overview
  64. 8.11.3 NovaDel Pharma GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 NovaDel Pharma GABA Receptor Agonist Drug Product Portfolio
  66. 8.11.5 NovaDel Pharma Recent Developments
  67. 8.12 H.LundBeck, Merck and Co
  68. 8.12.1 H.LundBeck, Merck and Co Company Information
  69. 8.12.2 H.LundBeck, Merck and Co Business Overview
  70. 8.12.3 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Product Portfolio
  72. 8.12.5 H.LundBeck, Merck and Co Recent Developments
  73. 8.13 Elan Corporation
  74. 8.13.1 Elan Corporation Company Information
  75. 8.13.2 Elan Corporation Business Overview
  76. 8.13.3 Elan Corporation GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Elan Corporation GABA Receptor Agonist Drug Product Portfolio
  78. 8.13.5 Elan Corporation Recent Developments
  79. 8.14 Biocodex
  80. 8.14.1 Biocodex Company Information
  81. 8.14.2 Biocodex Business Overview
  82. 8.14.3 Biocodex GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Biocodex GABA Receptor Agonist Drug Product Portfolio
  84. 8.14.5 Biocodex Recent Developments
  85. 8.15 Athena Drug Delivery Solutions
  86. 8.15.1 Athena Drug Delivery Solutions Company Information
  87. 8.15.2 Athena Drug Delivery Solutions Business Overview
  88. 8.15.3 Athena Drug Delivery Solutions GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Athena Drug Delivery Solutions GABA Receptor Agonist Drug Product Portfolio
  90. 8.15.5 Athena Drug Delivery Solutions Recent Developments
  91. 8.16 Advicenne
  92. 8.16.1 Advicenne Company Information
  93. 8.16.2 Advicenne Business Overview
  94. 8.16.3 Advicenne GABA Receptor Agonist Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Advicenne GABA Receptor Agonist Drug Product Portfolio
  96. 8.16.5 Advicenne Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GABA Receptor Agonist Drug Value Chain Analysis
  2. 9.1.1 GABA Receptor Agonist Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GABA Receptor Agonist Drug Sales Mode & Process
  6. 9.2 GABA Receptor Agonist Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GABA Receptor Agonist Drug Distributors
  9. 9.2.3 GABA Receptor Agonist Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst